Beijing Biocytogen Co., LTD
Gene Editing Services:
As the cornerstone since the company’s inception, Biocytogen’s Gene Editing Division is responsible for the technical R&D of gene editing services, supplying custom, gene-edited animal models and cell lines to domestic and international customers, and for supporting internal product development within the company. Over the past ten years, the Gene Editing Division has established a reliable and efficient large-scale technical platform. This platform offers a comprehensive array of animal and cell model services by using several methodologies including traditional mouse embryonic stem cell (ESC)/homologous recombination (HR) technology, CRISPR/Cas9-based Extreme Genome Editing (EGE) technology, and extra-large fragment gene recombination technology (Mb scale) based on chromosome engineering. In 2018, more than 1,500 gene editing projects were delivered to customers around the world. Moreover, Biocytogen’s immune checkpoint, cytokine (receptor) humanized mice, the highly immune-deficient (B-NDG®) mice and RenMab mice are being widely used by multinational pharmaceutical R&D companies.
Biocytogen’s Preclinical Services Division, currently focused in immuno-oncology, oncology, and autoimmunity, has established comprehensive in vivo and in vitro pharmacology capabilities and provided world-class services to a broad spectrum of our customers.
At the core of our in vivo services are a large collection of genetically humanized mouse models of checkpoint inhibitors and cytokine/cytokine receptors, our highly immune-deficient B-NDG mice and their variants, including human immune reconstituted models using human PBMC and CD34+ engraftment, CDX (cell line-derived xenografts) and PDX (patient-derived xenografts) models, and efficient engineering of desired cell line models for both in vivo and in vitro application. Based upon these models, our in vivo pharmacology platform provides in vivo efficacy, pharmacokinetics (PK), pharmacodynamics (PD) and biomarkers, and pathology and toxicology assessments. Complementary to our in vivo capabilities, our in vitro pharmacology platform performs immune cell profiling (e.g. tumor infiltrating lymphocytes (TIL) analysis), cytokine profiling, primary T, NK, and macrophage cell-based functional assays such as T cell activation, mixed-lymphocyte reaction (MLR), T cell cytotoxicity, antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), target binding, receptor occupancy (RO), cell proliferation and cell death, and cell reporter assays.
We have successfully supported our pharmaceutical and biotech customers in evaluating therapeutics of multiple forms, including biologics (monoclonal antibodies, bispecific antibodies, and recombinant proteins), peptides, small molecules, cell therapy of CAR-T, and oncolytic viruses. In 2018, our Preclinical Services Division has completed over 500 drug evaluation projects for more than 200 partners worldwide. We also successfully assisted our customers in IND applications. Supported by Biocytogen’s large-scale generation of new animal models and advanced gene editing technology, our Preclinical Services Division will continue to deliver high-quality, timely and cost-effective services, provide comprehensive and accurate data, and facilitate the drug discovery and development processes for our customers.
Antibody Discovery Services:
Combining the characteristics and advantages of Biocytogen, the antibody drug development service platform has established a unique set of antibody development technology processes, providing partners with efficient services, and completing the entire process from antibody discovery to IND filing. The advantages of the Biocytogen antibody platform are multifold: First, the high-throughput hybridoma screening and single-cell sequencing technology is combined with the company’s independently developed fully human antibody mouse RenMab, and the antibody platform can achieve the preparation of therapeutic fully human antibody in one stop. The innovative RenMab technology eliminates the need for humanization of the murine antibody; Second, most biopharmaceuticals, especially antibody drugs, are species-specific, posing a difficulty for preclinical evaluation of efficacy and safety. The antibody platform utilizes novel immune checkpoint humanized mouse models generated in house, thus we can quickly complete the in vivo pharmacodynamics screening and validation of antibodies, maximizing the effectiveness of lead molecules; Last, our state-of-art lab is well suited for full characterization and optimization of antibody molecules, including biological activity, affinity analysis, binding activity, physicochemical properties analysis, antibody engineering, antibody subtype selection, etc. Since its establishment in 2016, the antibody platform has completed more than twenty antibody development projects for its partners. The project cycle can be shortened to 8 months from project approval to completion.
Address: 88 No.6 Kechuang Street, Building C, 12th Floor Beijing Economic and Technological Dvelopment Area, Yizhuang, Beijing, 101111, China
Haimen Animal Center (Biocytogen Jiangsu Co., Ltd)
Biocytogen’s Haimen Animal Center is located in Linjiang New District, Haimen City, Jiangsu Province, which is a one-hour drive from Shanghai. Since the company’s operation in April 2016, it has obtained Jiangsu Province’s Experimental Animal Production License and import and export qualifications. In October 2016, the company achieved AAALAC accreditation. The first building of the Haimen Animal Center facility covers an area of 15,000 m2 and is designed for breeding and supply of Biocytogen’s animal model products. Since May 2019, the Haimen Animal Center has supplied highly immune-deficient B-NDG® mice, single and double immune checkpoint humanized models such as B-hPD-1 and B-hPD-1/B-hPDL-1 mice, cytokine (receptor) humanized mice, and hundreds of gene-edited humanized mice for corresponding drug targeting studies. The second animal facility in Haimen, “Biocytogen China Animal Model Base Project”, is currently under construction; it covers an area of 100,000 m2 and is equipped with animal housing rooms, laboratory animal facilities, animal laboratories and project incubation centers that meet international standards. The new facility is expected to be operational by the end of 2019. With a wide range of animal models, high-quality and large scale production, Biocytogen has become a long-term and stable model animal supplier for domestic and overseas research institutes and pharmaceutical companies. Biocytogen’s Haimen Animal Center has supplied animals to partners in more than 20 countries and regions that include North America, Europe, and Asia Pacific.
Address: B12 building, Biotech and Pharmaceutical Park, Linjiang New District, Haimen, 226100 Jiangsu
Biocytogen Boston Corporation
Established in the greater Boston area in 2018, Biocytogen Boston Corporation provides preclinical pharmacology services to clients in the United States and abroad. Biocytogen has generated a comprehensive preclinical in vivo efficacy and ex vivo/in vitro pharmacology service platform. This includes Biocytogen’s proprietary Immuno-Oncology (I/O) immune checkpoint mouse models, human immune-reconstituted (human PBMC, CD34+ HSC) B-NDG® (immunodeficient) mouse models, and many genetically engineered tumor cell lines. In addition to an emphasis on I/O, autoimmune and inflammatory diseases, Biocytogen also offers a variety of CDX and syngeneic mouse tumor models in our Boston site. We perform in vivo efficacy and safety evaluation services on therapeutic candidates (including antibodies and CAR-Ts) for biotech and pharmaceutical companies.
Our experienced and adept in vitro pharmacology team also provides an array of services including immune cell profiling and cytokine analysis. Our team also provides biochemical/molecular analyses and immune cell functional assays using human and rodent primary cells including MLR, ADCC, and CDC assays.
Moreover, Biocytogen Boston boasts a strong antibody R&D team. Combining our proprietary RenMab (fully human Ig) mouse model with our high-throughput antibody in vivo efficacy screening platform allows us to rapidly develop novel therapeutic antibody candidates. We are actively looking for a partnership to co-develop innovative therapeutic antibodies using the RenMab platform.
Address: 50C Audubon Road, Wakefield, MA 01880, USA